NTGN News and Press, Neon Therapeutics Inc. From 05/08/19

CAMBRIDGE, Mass., May 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Bank of Ameri...

Quick Take Hookipa Pharma ( HOOK ) has filed proposed terms to raise $100 million in a U.S. IPO, per an amended registration statement . Hookipa is advancing a pipeline of immunotherapeutics for infectious diseases and cancers. HOOK has generated promising trial results for its lead can...

CAMBRIDGE, Mass., April 08, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the completion of enrollment in NT-002, its Phase 1b clinical trial evaluating NEO-PV-01 with KEYTR...

Gainers:  Ocean Power Technologies (NASDAQ: OPTT ) +176% . Netshoes (Cayman) (NYSE: NETS ) +23% . Evogene (NASDAQ: EVGN ) +22% . Zynerba Pharmaceuticals (NASDAQ: ZYNE ) +21% . DMC Global (NASDAQ: BOOM ) +19% . Fuel Tech (NASDAQ: FTEK ) +18% . VivoPower International (NASDAQ: VVP...

Thinly traded micro cap Neon Therapeutics ( NTGN +9.9% ) is up on average volume following the release of updated data from a Phase 1b clinical trial, NT-001 , evaluating personalized neoantigen vaccine NEO-PV-01, combined with Bristol-Myers Squibb's ( BMY -0.3% ) Opdivo (nivolumab), ...

Post-Vaccine Immune and Pathologic Markers Associated with Durable Clinical Benefit in Metastatic Melanoma Patient Cohort Top-line Results, Including 52-Week Clinical Outcomes, from Full NT-001 Trial in Melanoma, Non-Small Cell Lung and Bladder Cancers Expected Later in 1H 2019 CAM...

Noteworthy events during the week of March 24 - 30 for healthcare investors. More news on: Cidara Therapeutics, Inc., Recro Pharma, Inc., Autolus Therapeutics plc, Healthcare stocks news, , Read more ...

Neon Therapeutics (NASDAQ: NTGN ): Q4 GAAP EPS of -$0.84. Cash, cash equivalents and marketable securities $103.3M Press Release More news on: Neon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, ,

CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the fourth quarter and full-year ended December 31, 2018 and pr...

CAMBRIDGE, Mass., March 04, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (Nasdaq: NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced that Hugh O’Dowd, Chief Executive Officer of Neon, will present at the Cowen and C...